Neal, Joel W.

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage

Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., et al. (2014) · Nature Medicine

Cancer Genomics and DiagnosticsPrenatal Screening and Diagnostics

Cited by 2,220

Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

Sequist, L. V., Soria, J.-C., Goldman, J. W., Wakelee, H. A., Gadgeel, S. M., Varga, A., Papadimitrakopoulou, V., Solomon, B. J., Oxnard, G. R., Dziadziuszko, R., et al. (2015) · New England Journal of Medicine

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 665

EGFR -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes

Marcoux, N., Gettinger, S. N., O’Kane, G., Arbour, K. C., Neal, J. W., Husain, H., Evans, T. L., Brahmer, J. R., Muzikansky, A., Bonomi, P. D., et al. (2019) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 500

A Vision-Language Foundation Model for Precision Oncology

Xiang, J., Wang, X., Zhang, X., Xi, Y., Eweje, F., Chen, Y., Li, Y., Bergstrom, C., Gopaulchan, M., Kim, T., et al. (2025) · Nature

AI in cancer detectionMultimodal Machine Learning Applications

Cited by 256

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Skoulidis, F., Araujo, H. A., Do, M. T., Qian, Y., Sun, X., Galan-Cobo, A., Le, J. T., Montesion, M., Palmer, R., Jahchan, N., et al. (2024) · Nature

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 194

Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor–Induced Myocarditis

Zhu, H., Galdos, F. X., Lee, D., Waliany, S., Huang, Y. V., Ryan, J., Dang, K., Neal, J. W., Wakelee, H. A., Reddy, S. A., et al. (2022) · Circulation

Cancer Immunotherapy and BiomarkersViral Infections and Immunology Research

Cited by 192

Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips

Earhart, C. M., Hughes, C. E., Gaster, R. S., Ooi, C. C., Wilson, R. J., Zhou, L. Y., Humke, E. W., Xu, L., Wong, D. J., Willingham, S. B., et al. (2014) · Lab Chip

Microfluidic and Bio-sensing TechnologiesMicrofluidic and Capillary Electrophoresis Applications

Cited by 165

Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery

Chiou, S.-H., Tseng, D., Reuben, A., Mallajosyula, V., Molina, I. S., Conley, S., Wilhelmy, J., McSween, A. M., Yang, X., Nishimiya, D., et al. (2021) · Immunity

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 133

Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer

Heist, R. S., Duda, D. G., Sahani, D. V., Ancukiewicz, M., Fidias, P., Sequist, L. V., Temel, J. S., Shaw, A. T., Pennell, N. A., Neal, J. W., et al. (2015) · Proceedings of the National Academy of Sciences

Angiogenesis and VEGF in CancerLung Cancer Treatments and Mutations

Cited by 126

Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study

Saad, M. B., Hong, L., Aminu, M., Vokes, N. I., Chen, P., Salehjahromi, M., Qin, K., Sujit, S. J., Lu, X., Young, E., et al. (2023) · The Lancet Digital Health

Radiomics and Machine Learning in Medical ImagingCancer Immunotherapy and Biomarkers

Cited by 121

Developing biomarker-specific end points in lung cancer clinical trials

Neal, J. W., Gainor, J. F., & Shaw, A. T. (2015) · Nature Reviews Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 51

P1.13-44 Safety, PK, and Preliminary Antitumor Activity of the Oral EGFR/HER2 Exon 20 Inhibitor TAK-788 in NSCLC

Neal, J., Doebele, R., Riely, G., Spira, A., Horn, L., Piotrowska, Z., Costa, D., Zhang, S., Bottino, D., Zhu, J., et al. (2018) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 28

Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non–small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study.

Neal, J. W., Santoro, A., Viteri, S., Ponce Aix, S., Fang, B., Lim, F. L., Gentzler, R. D., Goldschmidt, J. H., Khrizman, P., Massarelli, E., et al. (2022) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 18